Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.182
Buy
RSI(14)
67.575
Neutral
STOCH(KDJ)(9,3,3)
86.162
Buy
ATR(14)
1.630
High Vlolatility
CCI(14)
180.353
Buy
Williams %R
1.725
Overbought
TRIX(12,20)
0.085
Sell
StochRSI(14)
100.000
Buy
AstraZeneca PLC
AZNView Detailed Chart
74.260USD
-2.330-3.04%
Market hours （ET）Quotes delayed by 15 min
230.31BMarket Cap
29.63P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.04%
5 Days
+1.73%
1 Month
+6.27%
6 Months
+4.24%
Year to Date
+13.34%
1 Year
-4.67%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
13
analysts
BUY
Current Rating
100.382
Target Price
31.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
172
Total
5
Median
8
Average
Company name
Ratings
Analysts
AstraZeneca PLC
AZN
13
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Buy
Moving Average
Indicators
Value
Direction
MA5
73.748
Buy
MA10
71.899
Buy
MA20
71.256
Buy
MA50
71.383
Buy
MA100
71.208
Buy
MA200
70.584
Buy
News
George Soros’s Playbook in 2025: Opportunistic, Nimble, and Undeniably Contrarian
TradingKey - When ordinary investors hear George Soros's name, it evokes that hedge fund legend who “broke the Bank of England,” but today Soros Fund Management trades with a system that is far more complicated than speculating in currencies.
TradingKeyFri, Jul 4
AstraZeneca breast cancer drug shows positive results, shares up
Investing.com -- AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the illness during a late-stage clinical trial.
Investing.comWed, Feb 26
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
Feb 20 (Reuters) - AstraZeneca AZN.L will buy longtime partner FibroGen's FGEN.O China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second-biggest economy.
ReutersThu, Feb 20
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Ticker SymbolAZN
CompanyAstraZeneca PLC
CEOMr. Marc Dunoyer
Websitehttps://www.astrazeneca.com/
Related Instruments
-0.71%
-0.82%
+1.59%
-1.55%
-2.69%
-4.24%
-0.80%
-0.64%
-0.63%
-0.88%
-8.28%
-5.20%
-1.10%
-1.71%
-3.20%
-1.25%
-0.23%
+16.42%
+0.21%
+0.37%
